The world's first integrated home platform combining AI-powered early detection with breakthrough non-invasive brain therapy that treats and prevents dementia.
Prototype worn by Director of Engineering Bruce Kong B.Eng B.A.Sc
Over 400 million people worldwide are affected by dementia, with cases expected to triple by 2050. Despite this, up to 75% of cases remain undiagnosed until symptoms become severe.
We are currently in the clinical phase of our product development journey, with a pilot study of 8 people showing a reversal of mild dementia symptoms within just two weeks of treatment. We are currently raising funds to complete larger clinical trials.
Revolutionary dual-platform combining a non-invasive brain therapy with AI-powered early detection for home use.
The Amygo is a revolutionary device which undoes the damage of dementia by breaking apart the proteins in the brain that cause the disease and by stimulating neurogenesis.
Out first-of-its-kind diagnostic software allows for clinician-level screening all from the discretion of your own home. 75% of people with dementia go undiagnosed.1 Catching it before severe symptoms appear allows for better interventions.
Lightweight device attaches to baseball cap for seamless daily treatment
Our software allows for daily symptom tracking, giving peace of mind to caretakers. Used with our device, the evidence of recovery is in your hands.
Our latest prototype of our on-invasive medical device (Class-II)
Compared to existing solutions, Amygo delivers superior outcomes with fewer risks.
We envision a world where dementia no longer exists, and Amygo devices are a regular part of informed self-care as common as home blood pressure monitors.
Be part of the breakthrough technology that will transform how the world prevents and treats dementia.